KLRA1P and neoplasm: We have previously shown that the pan anti-MHC-mAbs, M1/42 in the mouse, and W6/32 and DX17 in the human, that block engagement of tumor cells by the Ly49 or LILR inhibitory receptors on NK or myeloid cells, result in strong anti-tumor responses11–13.